Citations

Clear

4201 citation(s) found for "Chen, Chen".

Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States
Muffly, Lori , Pasquini, Marcelo C. , Martens, Michael J. , Brazauskas, Ruta , Zhu, Xiaochun , Adekola, Kehinde , Aljurf, Mahmoud , Ballen, Karen K. , Baron, Frédéric , Beitinjaneh, Amer , Cahn, Jean‐Yves, Carabasi, Mathew, Chen, Yi‐Bin , Ciurea, Stefan O. , Copelan, Edward A. , D’Souza, Anita , Edwards, John , Foran, James M. , Freytes, César O. , Fung, Henry C., Hashmi, Shahrukh K. , Hildebrandt, Gerhard , Ho, Vincent T. , Jakubowski, Ann A. , Luskin, Marlise R. , Martino, Rodrigo , Olin, Rebecca L. , Olsson, Richard F. , Pawarode, Attaphol , Peres, Edward, Rezvani, Andrew R. , Rizzieri, David A. , Schouten, Harry C. , Sabloff, Mitchell , Seftel, Matthew D. , Seo, Sachiko , Sorror, Mohamed L. , Wirk, Baldeep , Wood, William A. , Bajel, Ashish R. , Battiwalla, Minoo , Cahn, Jean‐Yves , Chhabra, Saurabh , Gale, Robert Peter , Giralt, Sergio , Lazarus, Hillard M. , Luskin, Marlise R , Maziarz, Richard Thomas , McCarthy, Philip L. , Nishihori, Taiga , Savani, Bipin N. , Szer, Jeff , Artz, Andrew , D'Souza, Anita , Olsson, Richard F , Martino, Rodrigo , Muffly, Lori , Sabloff, Mitchell , Martens, Michael J , Sorror, Mohamed , Wood, William A

Mayo Clinic

Blood | July 3, 2017 | Volume: 130 | Issue: 9 | Pages: 1156-1164

10.1182/blood-2017-03-772368 | PMID 28674027 Get It

Key Points Over the last decade, allogeneic HCT has been increasingly administered in the United States to adults aged 70 and older with hematologic malignancies. Allogeneic transplant outcomes were reasonable; high comorbidity and ablative conditioning regimens were associated with inferior outcomes.
Photodynamic Therapy With Hematoporphyrin Derivative in the Treatment of Superficial Transitional-Cell Carcinoma of the Bladder
Prout, George R., Lin, Chi‐Wei , Benson, Ralph C., Nseyo, U.O., Griffin, Pamela P., Kinsey, J. H. , Tian, Ming , Lao, Yi, Main, Y.-Z., Chen, X. , Qiao, Shuo, Daly, James J. , Tian, M.-E., Lao, Y.-H., Ren, F.-M., Qiao, S.-J.

Mayo Clinic

Journal of Urology | June 30, 2017 | Volume: 139 | Issue: 5 | Pages: 1132-1133

10.1016/s0022-5347(17)42809-6 Get It

Re: The Inability of Prostate Specific Antigen Index to Enhance the Predictive Value of Prostate Specific Antigen in the Diagnosis of Prostatic Carcinoma, by M. K. Brawer, E. A. G. Aramburu, G. L. Chen, S. D. Preston and W. J. Ellis, J. Urol., 150: 369-373
Jacobsen, Steven J. , Oesterling, Joseph E., Guess, Harry A.

Mayo Clinic

Journal of Urology | June 30, 2017 | Volume: 151 | Issue: 5 | Pages: 1356-1356

10.1016/s0022-5347(17)35256-4 | PMID 7512666 Get It

Natural History of Prostatism: Urinary Flow Rates in A Community-Based Study
Panser, Laurel A., Oesterling, Joseph E., Arrighi, H. Michael, Guess, H. A., Lieber, Michael M., Girman, Cynthia J. , Chute, Christopher G. , Barrett, David M. , Chen, Chu‐Chih

Mayo Clinic

Journal of Urology | June 30, 2017 | Volume: 150 | Issue: 3 | Pages: 887-892

10.1016/s0022-5347(17)35640-9 | PMID 7688433 Get It

A Diver With Double Vision
Arora, Nitika, Garrity, James A., Chen, John J. , Chen, John J

Mayo Clinic

JAMA Ophthalmology | June 29, 2017 | Volume: 135 | Issue: 9 | Pages: 1001

10.1001/jamaophthalmol.2017.0660 | PMID 28662234 Get It

Hypermethylation of Synphilin-1, Alpha-Synuclein-Interacting Protein (SNCAIP) Gene in the Cerebral Cortex of Patients with Sporadic Parkinson’s Disease
Tafreshi, Ali , Beach, Thomas G. , Tashiro, Stephanie, Wang, Charles , Dashtipour, Khashayar , Adler, Charles H. , Chen, Xin , Serrano, Geidy E. , Tashiro, Stephanie

Mayo Clinic

Brain Sciences | June 28, 2017 | Volume: 7 | Issue: 7 | Pages: 74

10.3390/brainsci7070074 | PMID 28653979 Get It

Objective: To determine and compare DNA methylation patterns between patients with Parkinson’s disease (PD) and age- and sex-similar matched non-PD controls. Background: Epigenetic regulation is one of the major mechanisms for an organism to respond to the environment through changes in gene expression and has been implicated in numerous disease processes. We would like to examine epigenetic modification patterns that may predispose or protect against PD. Methods: Frozen tissue samples of the human cerebral cortex from 12 PD patients and 12 subjects without PD pathology were obtained. Genome-wide DNA methylation profiling was performed using the Illumina HumanMethylation450 BeadChip array. Differential methylation was defined as a mean methylation level difference (delta β) of at least 0.20 (Δβ ≥ 0.20). Methylation regions with an absolute delta β value ≥ 0.20 were selected for further gene function studies. Results: We identified 2795 differentially methylated CpG sites in the frontal cortex of PD cases with a detection p-value of ≤ 0.01 and 328 differentially methylated CpG sites with a detection p-value of ≤ 0.001. A pattern of robust hypermethylation of synphilin-1, α-synuclein-interacting protein (SNCAIP) gene was found in the brain of PD cases (p = 4.93 × 10−7 and delta β = 0.60). Conclusion: Our findings support a link between SNCAIP methylation and PD risk. Hypomethylation of SNCAIP may function to protect against PD. The current results may suggest that the methylation status of SNCAIP could be useful as a marker in PD diagnosis and treatment and warrants further investigation.
Quality-of-Life (QOL) during Screening for Phase 1 Trial Studies in Patients with Advanced Solid Tumors and Its Impact on Risk for Serious Adverse Events
Anwar, Sidra , Tan, Wei, Hong, Chi-Chen, Admane, Sonal , Dozier, Askia, Siedlecki, Francine, Whitworth, Amy, DiRaddo, Ann Marie, DePaolo, Dawn, Jacob, Sandra M, Miller, Austin , Adjei, Alex A. , Dy, Grace K. , Ma, Wen Wee, Hong, Chi‐Chen , Wee, Wen , Miller, Austin

Mayo Clinic

Cancers | June 27, 2017 | Volume: 9 | Issue: 7 | Pages: 73

10.3390/cancers9070073 | PMID 28672850 Get It

Background: Serious adverse events (SAEs) and subject replacements occur frequently in phase 1 oncology clinical trials. Whether baseline quality-of-life (QOL) or social support can predict risk for SAEs or subject replacement among these patients is not known. Methods: Between 2011–2013, 92 patients undergoing screening for enrollment into one of 22 phase 1 solid tumor clinical trials at Roswell Park Cancer Institute were included in this study. QOL Questionnaires (EORTC QLQ-C30 and FACT-G), Medical Outcomes Study Social Support Survey (MOSSSS), Charlson comorbidity scores (CCS) and Royal Marsden scores (RMS) were obtained at baseline. Frequency of dose limiting toxicities (DLTs), subject replacement and SAEs that occurred within the first 4 cycles of treatment were recorded. Fisher’s exact test and Mann-Whitney-Wilcoxon test were used to study the association between categorical and continuous variables, respectively. A linear transformation was used to standardize QOL scores. p-value ≤ 0.05 was considered statistically significant. Results: Baseline QOL, MOSSSS, CCS and RMS were not associated with subject replacement nor DLTs. Baseline EORTC QLQ-C30 scores were significantly lower among patients who encountered SAEs within the first 4 cycles (p = 0.04). Conclusions: Lower (worse) EORTC QLQ-C30 score at baseline is associated with SAE occurrence during phase 1 oncology trials.
Translation repression via modulation of the cytoplasmic poly(A)-binding protein in the inflammatory response
Zhang, Xu , Chen, Xiaoli , Liu, Qiuying , Zhang, Shaojie , Hu, Wenqian , Hu, Wenqian , Zhang, Xu

Mayo Clinic

eLife | June 21, 2017 | Volume: 6 | Issue: No issue available | Pages: No page available

10.7554/elife.27786 | PMID 28635594 Get It

Gene expression is precisely regulated during the inflammatory response to control infection and limit the detrimental effects of inflammation. Here, we profiled global mRNA translation dynamics in the mouse primary macrophage-mediated inflammatory response and identified hundreds of differentially translated mRNAs. These mRNAs’ 3’UTRs have enriched binding motifs for several RNA-binding proteins, which implies extensive translational regulatory networks. We characterized one such protein, Zfp36, as a translation repressor. Using primary macrophages from a Zfp36-V5 epitope tagged knock-in mouse generated by CRISPR/Cas9-mediated genome editing, we found that the endogenous Zfp36 directly interacts with the cytoplasmic poly(A)-binding protein. Importantly, this interaction is required for the translational repression of Zfp36’s target mRNAs in resolving inflammation. Altogether, these results uncovered critical roles of translational regulations in controlling appropriate gene expression during the inflammatory response and revealed a new biologically relevant molecular mechanism of translational repression via modulating the cytoplasmic poly(A)-binding protein.
Early Markers of Angiogenesis and Ischemia during Bowel Conduit Neovascularization
Ciudad, Pedro , Torto, Federico Lo , Li, Yun-Fen , Nguyen, Doan-Minh, Chen, Hung‐Chi , Manrique, Oscar J. , Chen, Hung‐Chi , Wong, Alex K. , Chen, Pei‐Yu

Mayo Clinic

Journal of Reconstructive Microsurgery | June 19, 2017 | Volume: 33 | Issue: 09 | Pages: 605-611

10.1055/s-0037-1603905 | PMID 28628933 Get It

Background Bowel flaps are a good and reliable method to restore the continuity of the aerodigestive tract. Radiated fields, contaminated recipient sites, or depleted recipient vessels may increase the risk for ischemic injury after transfer. During ischemic events, we believe that bowel conduits with serosa have a delayed neovascularization process at its new recipient site.We conducted an ischemia/reperfusion murine model to understand the difference among bowel conduits with and without serosa. Materials and Methods Two groups of rats were compared: control group (jejunal conduit with serosa) and a target group (jejunal conduit without serosa). These conduits were harvested from the peritoneal cavity and transferred into a subcutaneous pocket. After 72 hours of transfer and pedicle ligation, histological changes related to ischemia/reperfusion were assessed. In addition, tissue markers of angiogenesis (CD34), ischemia (lactate dehydrogenase [LDH]), and inflammation (interleukin [IL]-1β and IL-6) were analyzed. Results Two groups (n = 20) of male rats were analyzed. Histology showed intact jejunal mucosa in the target group. The control group showed decreased number of mucin, globet cells, decreased height, and fragmentation of villi with the absence of intestinal glands. Markers of angiogenesis (CD34) were higher in the target group. In addition, markers of ischemia (LDH) (p = 0.0045) and inflammation (IL-1b, p = 0.0008, and IL-6, p = 0.0008) were significantly lower in the target group as compared with the control group. Conclusions In circumstances in which the recipient site does not offer an adequate and healthy bed or a vascular insult occurs, bowel flaps with less amount of serosa may be able to neovascularize faster thereby increasing its chances of survival.